Novartis Launches Fanapt In US For Schizophrenia Treatment
In clinical trials, treatment with Fanapt resulted in improvement in symptoms of schizophrenia compared to patients on placebo, as demonstrated on two major scales for measuring the positive
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK.
The Phase 2a study has demonstrated proof-of-concept for DR Cysteamine, which is Raptor’s proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule.